ಇಂದು ವೃಶ್ಚಿಕ ರಾಶಿಯಲ್ಲಿ ಚಂದ್ರನ 12 ರಾಶಿಗಳ ಫಲಾಫಲ ಹೇಗಿದೆ..?
- Opko Health Inc said on Wednesday it signed a deal with Merck & Co Inc potentially worth up to $922.5 million for its experimental Epstein-Barr virus vaccine.
(Adds share moves)
March 8 (Reuters) - Opko Health Inc said on Wednesday it signed a deal with Merck Co Inc potentially worth up to $922.5 million for its experimental Epstein-Barr virus vaccine.
Shares of Opko jumped 28% in premarket trade.
Merck will take over the clinical and regulatory activities related to the vaccine, as well its commercialization once the drugmaker files a joint application with Opko unit ModeX Therapeutics to test it in humans, the company said.
Opko will receive an upfront payment of $50 million and is eligible for milestone payments of up to $872.5 million, plus royalties on global sales.
There is currently no vaccine for the Epstein-Barr virus, which is the leading cause of mononucleosis, or mono, commonly called the "kissing disease". (Reporting by Aditya Samal in Bengaluru; Editing by Pooja Desai)
ತಾಜಾ ಮಾಹಿತಿ ಪಡೆಯಲು ಪ್ರಜಾವಾಣಿ ಟೆಲಿಗ್ರಾಂ ಚಾನೆಲ್ ಸೇರಿಕೊಳ್ಳಿ
ತಾಜಾ ಸುದ್ದಿಗಳಿಗಾಗಿ ಪ್ರಜಾವಾಣಿ ಆ್ಯಪ್ ಡೌನ್ಲೋಡ್ ಮಾಡಿಕೊಳ್ಳಿ: ಆಂಡ್ರಾಯ್ಡ್ ಆ್ಯಪ್ | ಐಒಎಸ್ ಆ್ಯಪ್
ಪ್ರಜಾವಾಣಿ ಫೇಸ್ಬುಕ್ ಪುಟವನ್ನುಫಾಲೋ ಮಾಡಿ.